Novo Nordisk, Ozempic
Novo Nordisk weight-loss drug is effective for kids as young as 6, study shows
A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6 when combined with diet and exercise, a small new study shows.
A Novo Nordisk weight loss drug lowers BMI in kids as young as 6
In a late-stage clinical trial, a drug similar to Ozempic was shown to reduce body mass index in kids ages 6 to 11 with obesity, according to results published Tuesday in the New England Journal of Medicine.
Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s pipeline of next-generation candidates.
Novo Nordisk claims obesity drug effective for under-12s
There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University of Minnesota Medical School who led the study, which will also be published in the New England Journal of Medicine.
Eli Lilly, Novo Nordisk and other Big Pharmas back OAC’s ‘Your Weight Matters’ campaign challenge
Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” campaign—and it’s got some big-name backers to help. | Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” campaign—and it’s got some big-name backers to help.
Novo Nordisk's Ozempic shortage expected to continue into Q4
Novo Nordisk said the shortage of lower strengths of its diabetes drug Ozempic has deteriorated, with intermittent shortages for all strengths expected into the final quarter of 2024 due to increased demand and along with capacity constraints at some of its manufacturing sites.
Novo Nordisk’s Ozempic Shortage Is Worsening. That’s Good for Eli Lilly Stock.
While Novo is struggling to keep up with demand for its obesity drugs, U.S. rival Eli Lilly sees supply restraints easing.
Novo Nordisk Warns Of Weight Loss Drug Shortage
Novo Nordisk (NVO) is warning about a growing shortage of its popular weight loss drug Ozempic. The Danish pharmaceutical company has issued a statement saying that the current shortage of Ozempic, which is also used to treat diabetes,
Novo Nordisk experimental obesity pill has mild-to-moderate side effects in early trial
Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial; Cuts Body Weight By 13 Percent
Danish pharma giant Novo Nordisk has reported promising data on its new weight loss pill, which has been shown to lower body ...
Obesity drugs in kindergarten? Novo Nordisk GLP-1 drug works for kids as young as 6, study finds.
Amid an ongoing debate over what role, if any, GLP-1 medications should play in treating children who are still in elementary ...
Novo's older obesity drug is safe and effective for children, study finds
Novo Nordisk's older weight-loss drug Saxenda helped children between the ages of 6 and under 12 reduce their body mass index ...
The Financial Express1h
Novo Nordisk experimental obesity pill found to be safe and tolerable in early trial
Existing obesity drugs like Wegovy and Eli Lilly's Zepbound are injectable. Pills require larger amounts of active ...
Benefits Pro12h
Novo Nordisk files patent claims to fend off generic rivals
Sun Pharma of India and Mylan Pharmaceuticals of West Virginia seek FDA approval of generic versions of the popular ...
Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...
PipelineReview.com13h
Kallyope Announces License Agreement with Novo Nordisk
Novo Nordisk exercises option to license Kallyope-identified ligand for therapeutic development including potential treatment for obesity ...